Yelena Y. Janjigian, MD

Articles

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Janjigian on the Importance of Routine HER2 Testing in Gastric/GEJ Cancer

January 13th 2021

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer

January 7th 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

Dr. Janjigian on the Emergence of New Treatment Options in Esophageal and Gastric Cancer

December 11th 2020

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

November 24th 2020

Yelena Y. Janjigian, MD, discusses the importance of selecting an optimal first-line therapy in gastric cancer.

Dr. Janjigian on the Importance of Biomarker Testing in GI Cancers

November 19th 2020

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer

June 25th 2020

Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.

Dr. Janjigian on Pembrolizumab Triplet in HER2+ Esophagogastric Cancer

June 17th 2020

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Dr. Janjigian on Extensive Intraoperative Peritoneal Lavage in Gastric Cancer

April 21st 2020

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Dr. Janjigian on the JAVELIN Gastric 100 Study With Avelumab in Gastric/GEJ Cancer

April 14th 2020

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Dr. Janjigian on Data With Atezolizumab/Bevacizumab Combo in HCC

January 11th 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

Dr. Janjigian on Immunotherapy Combinations in Gastric Cancer

March 29th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the addition of checkpoint inhibitors to the treatment landscape for patients with gastric and esophageal cancer, as well as potential combinations being investigated.

Dr. Janjigian on Immunotherapy in Esophageal and Gastric Cancer

January 26th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with gastric and esophageal cancer.

Dr. Janjigian on Conducting MSI Testing in Gastric Cancer

January 13th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses when to conduct microsatellite instability (MSI) testing for patients with gastric cancer.

Dr. Janjigian Discusses MSI Testing in Gastric Cancer

September 19th 2017

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Dr. Janjigian Discusses Afatinib and Cetuximab for Patients With EGFR-Mutant Lung Cancer

August 4th 2014

Yelena Y. Janjigian, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses results of an early-phase study looking at afatinib and cetuximab for patients with EGFR-mutant lung cancer.